Sodium-Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions.

Key Summary Points

Digital Features

To view digital features for this article go to https://doi.org/10.6084/m9.figshare.13041794.

Dear Editor,

In their anecdotal report, Bossi and colleagues demonstrate that “off-label” use of sodium–glucose cotransporter 2 (SGLT2) inhibitors in three subjects with severe or critical severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia without diabetes did not have a significant impact on surrogate clinical outcomes, such as length of hospital stay [1]. In another recent retrospective analysis, Dalan et al. provide significant evidence regarding the impact of different antihypertensive and antihyperglycemic drug classes on coronavirus disease 2019 (COVID-19) “hard” outcomes [2]. Of note, the researchers demonstrated that among infected subjects with concomitant type 2 diabetes mellitus (T2DM), those prior treated with SGLT2 inhibitors (n = 16) featured a significantly lower risk of mechanical ventilation, after adjustment for baseline characteristics and other established cardiovascular risk factors [2]. The latter might have significant prognostic implications, based on the high mortality rates observed among patients that develop acute respiratory distress syndrome (ARDS) and are managed with mechanical ventilation [3].

Beyond their glucose-lowering effect, SGLT2 inhibitors exert pleiotropic effects (which are summarized by Bossi et al.), through which they provide substantial benefits in T2DM co-morbidities, such as cardiovascular disease, heart failure, and chronic kidney disease, all of which are associated with augmented risk of mortality from COVID-19 [4], while it is established that they confer cardiovascular benefit even in subjects without diabetes. The anti-inflammatory properties of SGLT2 inhibitors, mainly proven in experimental studies, might also be beneficial for patients with COVID-19, via amelioration of the so-called cytokine storm [5], despite the fact that its pathophysiologic significance has been recently doubted [6].

The major issue that arises against the use of SGLT2 inhibitors in patients with COVID-19 is the potentially increased risk of diabetic ketoacidosis (DKA) in the context of an acute infection [7, 8]. Protracted ketonemia, delay in DKA resolution, and high mortality among patients with COVID-19 and DKA pose significant concerns regarding the use of SGLT2 inhibitors in the acute setting, despite the fact that the rates of SGLT2 inhibitor usage in the aforementioned series were low [9, 10].

In conclusion, current evidence seems insufficient to influence decision-making for the management of patients in the acute setting, especially those without diabetes. An individualized treatment approach is advisable. Until then, we have to wait for the results of the Dapagliflozin in Respiratory Failure in Patients with COVID-19 (DARE-19) trial (ClinicalTrials.gov identifier NCT04350593) and larger observational studies, to elucidate the exact role of this drug class in the COVID-19 pandemic.

SGLT2 inhibitors seem to be a promising adjunct treatment option in patients with SARS-CoV-2 infection and co-morbidities, based on pathophysiologic mechanisms.

A major concern that arises is the increased risk of protracted ketonemia and diabetic ketoacidosis that are difficult to resolve.

Current evidence does not support the use of SGLT2 inhibitors in infected patients.